PANDA Trial

What is PANDA?

PANDA is a multi-center, double-blind, randomized, dose-ranging clinical trial to evaluate the efficacy and safety of Conbercept intravitreal injection in the treatment of patients with neovascular age-related macular degeneration. This project was initiated by Chengdu Kanghong Biotechnology Co., Ltd., a wholly-owned subsidiary of Kanghong Pharmaceutical Group.

Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular Age-related Macular Degeneration

Brief Summary:

The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept intravitreal (IVT) injection as compared to the approved vascular endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.

Condition or disease:

Neovascular Age-related Macular Degeneration

ntervention/treatmen:

Biological: 0.5 mg Conbercept Intravitreal Injection

Biological: 1.0 mg Conbercept Intravitreal Injection

Biological: 2.0 mg Aflibercept Intravitreal Injection